Sun Pharma Advanced Research Company Limited is reshuffling its leadership slate as it eyes a continued push toward its stated goal of becoming a global pharmaceutical leader. The board has approved the retirement of Rajamannar Thennati at the upcoming 21st Annual General Meeting, with his term concluding on August 10, 2026. In a move that signals continuity from within, Anil Raghavan has been appointed Managing Director and Chief Executive Officer, effective August 11, 2026, and will be subject to rotation, contingent on member approval at the AGM. Importantly, the company notes that Anil Raghavan is not related to any other director and is not debarred from holding the office of director by any authority.